295 related articles for article (PubMed ID: 26872106)
1. Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
Karakaya B; Tombak A; Serin MS; Tiftik N
Hematology; 2016 Jun; 21(5):295-9. PubMed ID: 26872106
[TBL] [Abstract][Full Text] [Related]
2. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.
Pépin M; Kleinjan A; Hajage D; Büller HR; Di Nisio M; Kamphuisen PW; Salomon L; Veyradier A; Stepanian A; Mahé I
J Thromb Haemost; 2016 Feb; 14(2):306-15. PubMed ID: 26589836
[TBL] [Abstract][Full Text] [Related]
3. Impact of the von Willebrand factor-ADAMTS-13 axis on the risk of future venous thromboembolism.
Edvardsen MS; Hansen ES; Ueland T; Aukrust P; Brækkan SK; Morelli VM; Hansen JB
J Thromb Haemost; 2023 May; 21(5):1227-1237. PubMed ID: 36736832
[TBL] [Abstract][Full Text] [Related]
4. Determination of vWF, ADAMTS-13 and Thrombospondin-1 in Venous Thromboembolism and Relating Them to the Presence of Factor V Leiden Mutation.
Al-Awadhi A; Marouf R; Jadaon MM; Al-Awadhy MM
Clin Appl Thromb Hemost; 2024; 30():10760296231223195. PubMed ID: 38225166
[TBL] [Abstract][Full Text] [Related]
5. ADAMTS-13 antigen and activity levels in thrombocytopenic disorders including thrombotic thrombocytopenic purpura in Kuwait.
Al-Awadhi AM; Jadaon MM; Al-Jafar HA; Al-Wazzan HJ
Acta Haematol; 2011; 125(3):160-6. PubMed ID: 21196718
[TBL] [Abstract][Full Text] [Related]
6. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura.
Zhou Z; Nguyen TC; Guchhait P; Dong JF
Semin Thromb Hemost; 2010 Feb; 36(1):71-81. PubMed ID: 20391298
[TBL] [Abstract][Full Text] [Related]
7. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
Tsai HM
J Mol Med (Berl); 2002 Oct; 80(10):639-47. PubMed ID: 12395148
[TBL] [Abstract][Full Text] [Related]
8. Increased ADAMTS13 activity in patients with venous thromboembolism.
Mazetto BM; Orsi FL; Barnabé A; De Paula EV; Flores-Nascimento MC; Annichino-Bizzacchi JM
Thromb Res; 2012 Dec; 130(6):889-93. PubMed ID: 23031329
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ADAMTS-13 by Doxycycline Reduces von Willebrand Factor Degradation During Supraphysiological Shear Stress: Therapeutic Implications for Left Ventricular Assist Device-Associated Bleeding.
Bartoli CR; Kang J; Restle DJ; Zhang DM; Shabahang C; Acker MA; Atluri P
JACC Heart Fail; 2015 Nov; 3(11):860-9. PubMed ID: 26454844
[TBL] [Abstract][Full Text] [Related]
10. Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis.
Favaloro EJ; Henry BM; Lippi G
Semin Thromb Hemost; 2021 Jun; 47(4):400-418. PubMed ID: 33893632
[TBL] [Abstract][Full Text] [Related]
11. Prospective Evaluation of the Pre-, Intra-, and Postoperative Kinetics of ADAMTS-13, von Willebrand Factor, and Interleukin-6 in Vascular Surgery.
Häußler KS; Keese M; Weber CF; Geisen C; Miesbach W
Clin Appl Thromb Hemost; 2020; 26():1076029620930273. PubMed ID: 33023308
[TBL] [Abstract][Full Text] [Related]
12. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome.
Lattuada A; Rossi E; Calzarossa C; Candolfi R; Mannucci PM
Haematologica; 2003 Sep; 88(9):1029-34. PubMed ID: 12969811
[TBL] [Abstract][Full Text] [Related]
13. von Willebrand factor/ADAMTS-13 interactions at birth: implications for thrombosis in the neonatal period.
Katneni UK; Ibla JC; Hunt R; Schiller T; Kimchi-Sarfaty C
J Thromb Haemost; 2019 Mar; 17(3):429-440. PubMed ID: 30593735
[TBL] [Abstract][Full Text] [Related]
14. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor.
Dong JF; Moake JL; Bernardo A; Fujikawa K; Ball C; Nolasco L; López JA; Cruz MA
J Biol Chem; 2003 Aug; 278(32):29633-9. PubMed ID: 12775718
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand Factor A2 domain polypeptide as substrate.
Cruz MA; Whitelock J; Dong JF
Thromb Haemost; 2003 Dec; 90(6):1204-9. PubMed ID: 14652658
[TBL] [Abstract][Full Text] [Related]
16. Changes in von Willebrand factor and ADAMTS-13 in patients following arthroplasty.
Liu L; Ling J; Ma Z; Yuan Q; Pan J; Yang H
Mol Med Rep; 2015 Apr; 11(4):3015-20. PubMed ID: 25482054
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.
Al-Awadhi A; Adekile A; Marouf R
J Thromb Thrombolysis; 2017 Jan; 43(1):117-123. PubMed ID: 27613177
[TBL] [Abstract][Full Text] [Related]
18. Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura.
Zheng XL
J Thromb Haemost; 2024 May; 22(5):1358-1365. PubMed ID: 38360215
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease.
Mannucci PM; Capoferri C; Canciani MT
Br J Haematol; 2004 Jul; 126(2):213-8. PubMed ID: 15238142
[TBL] [Abstract][Full Text] [Related]
20. Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent.
Jilma-Stohlawetz P; Quehenberger P; Schima H; Stoiber M; Knöbl P; Steinlechner B; Felli A; Jilma B
Thromb Res; 2016 Jan; 137():196-201. PubMed ID: 26616301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
